Morgan Stanley
RGC icon

Morgan Stanley’s Regencell Bioscience RGC Stock Holding History

Morgan Stanley’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$511K Sell
20,078
-1,346
-6% -$38.1K ﹤0.01% 5474
2025
Q4 		$450K Sell
21,424
-16,418
-43% -$267K ﹤0.01% 5564
2025
Q3 		$585K Buy
37,842
+4,822
+15% +$69.2K ﹤0.01% 5440
2025
Q2 		$563K Buy
33,020
+32,830
+17,279% +$400K ﹤0.01% 5413
2025
Q1 		$159 Sell
190
-79,610
-100% -$22K ﹤0.01% 7499
2024
Q4 		$10.4K Buy
+79,800
New +$12K ﹤0.01% 6787
2023
Q4 		– Sell
-12,388
Closed -$4.56K – 7894
2023
Q3 		$4.56K Buy
12,388
+950
+8% +$395 ﹤0.01% 6936
2023
Q2 		$6.53K Buy
11,438
+152
+1% +$102 ﹤0.01% 6923
2023
Q1 		$7.69K Buy
11,286
+608
+6% +$448 ﹤0.01% 6959
2022
Q4 		$7.64K Buy
10,678
+2,052
+24% +$1.57K ﹤0.01% 7029
2022
Q3 		$7K Buy
8,626
+2,964
+52% +$2.6K ﹤0.01% 7186
2022
Q2 		$5K Buy
5,662
+5,434
+2,383% +$4.1K ﹤0.01% 7406
2022
Q1 		$0 Buy
+228
New +$195 ﹤0.01% 8089
2021
Q4 		– Sell
-19,114
Closed -$11K – 8088
2021
Q3 		$11K Buy
+19,114
New +$8.62K ﹤0.01% 7291

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley's RGC Position: Q1 2026 in Review

Morgan Stanley reduced its Regencell Bioscience (RGC) stake by 6.3% in Q1 2026, selling an estimated $38.1K and leaving 20,078 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #5474.

Morgan Stanley first reported a position in RGC in Q3 2021 and has held it in 14 quarters since. The position peaked at $585K in Q3 2025. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Morgan Stanley held 20,078 shares of Regencell Bioscience worth $511K as of Q1 2026.
  • Morgan Stanley sold 1,346 Regencell Bioscience shares in Q1 2026, an estimated $38.1K.
  • Regencell Bioscience made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5474 holding.
  • Morgan Stanley first reported a position in Regencell Bioscience in Q3 2021 and has held it in 14 quarters since.
  • Morgan Stanley's Regencell Bioscience position peaked at $585K in Q3 2025.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.